室旁核注射胰高血糖素样肽-1对不同病程糖尿病大鼠胃排空的影响

目的:研究下丘脑室旁核(paraventricular nucleus,PVN)注射胰高血糖素样肽-1(GLP-1)对糖尿病早期大鼠胃排空的影响,并探讨其相关作用机制.方法:60只清洁级雄性Wistar大鼠随机分为正常对照组(NC组),糖尿病组(DM组),GLP-1干预组(GLP-1组),每组各20只,后两组腹腔注射链脲佐菌素(STZ)制备糖尿病模型,分别于注射STZ2周、6周后每组随机取半数进行实验,实验前于无菌条件下大鼠一侧下丘脑PVN区埋置套管,GLP-1组经套管注入GLP-1,NC组及DM组注入等体积生理盐水.酚红灌胃法检测胃排空率,酶联免疫吸附法(ELISA)测定血浆GLP-1浓度,半定量RT-PCR法测定胃窦、胃底GLP-1RmRNA表达.结果:注射STZ2周后,DM组较NC组胃排空率显著升高(P＜0.01).GLP-1组胃排空率低于DM组(P＜0.01),血浆GLP-1浓度高于DM组及NC组(P均＜0.05),胃窦GLP-1RmRNA表达明显高于DM组、NC组(P均＜0.01).注射STZ 6周后,DM组胃排空率高于NC组(P＜0.01).GLP-1组较DM组胃排空率显著降低(P＜0.01),血浆GLP-1浓度、胃窦GLP-1RmRNA表达显著高于DM组、NC组(P均＜0.01).结论:下丘脑PVN区注射GLP-1后,可减慢糖尿病大鼠初期加速的胃排空,原因可能与血浆GLP-1浓度及胃窦GLP-1RmRNA表达增加有关.     

室旁核注射胰高血糖素样肽-1对不同病程糖尿病大鼠胃排空的影响（英文）

目的：研究下丘脑室旁核（paraventricular nucleus,PVN）注射胰高血糖素样肽-1（GLP-1）对糖尿病早期大鼠胃排空的影响,并探讨其相关作用机制。方法：60只清洁级雄性Wistar大鼠随机分为正常对照组（NC组）,糖尿病组（DM组）,GLP-1干预组（GLP-1组）,每组各20只,后两组腹腔注射链脲佐菌素（STZ）制备糖尿病模型,分别于注射STZ2周、6周后每组随机取半数进行实验,实验前于无菌条件下大鼠一侧下丘脑PVN区埋置套管,GLP-1组经套管注入GLP-1,NC组及DM组注入等体积生理盐水。酚红灌胃法检测胃排空率,酶联免疫吸附法（ELISA）测定血浆GLP-1浓度,半定量RT-PCR法测定胃窦、胃底GLP-1RmRNA表达。结果：注射STZ 2周后,DM组较NC组胃排空率显著升高（P〈0.01）。GLP-1组胃排空率低于DM组（P〈0.01）,血浆GLP-1浓度高于DM组及NC组（P均〈0.05）,胃窦GLP-1RmRNA表达明显高于DM组、NC组（P均〈0.01）。注射STZ 6周后,DM组胃排空率高于NC组（P〈0.01）。GLP-1组较DM组胃排空率显著降低（P〈0.01）,血浆GLP-1浓度、胃窦GLP-1RmRNA表达显著高于DM组、NC组（P均〈0.01）。结论：下丘脑PVN区注射GLP-1后,可减慢糖尿病大鼠初期加速的胃排空,原因可能与血浆GLP-1浓度及胃窦GLP-1RmRNA表达增加有关。     

室旁核注射GLP-1 及拮抗剂对大鼠胃组织nesfatin-1 表达的影响

目的:探讨下丘脑室旁核(pareventricular,PVN)注射胰高血糖素样肽-1(GLP-1)及其受体拮抗剂Exendin(9-39)后胃组织核组蛋白2(NUCB2)/nesfatin-1表达的影响。方法:选取48只雄性Wistar大鼠,随机分为6组,生理盐水组,四种不同剂量GLP-1组(0.003 nmol/10μL,0.03 nmol/10μL,0.3 nmol/10μL,3 nmol/10μL),30 nmol Exendin(9-39)+3 nmol GLP-1(E+G)组,每组8只。PVN区埋置套管并按每组要求分别经套管给予GLP-1及Exendin(9-39)等药物。给药2小时后处死大鼠并取胃组织,实时荧光定量RT-PCR法检测各组胃组织NUCB2 m RNA表达。另外生理盐水组,3 nmo L GLP-1组及E+G组每组分别随机取6只大鼠的部分胃组织,用免疫组织化学法测胃粘膜NUCB2/nesfatin-1蛋白的表达情况。结果:实时荧光定量RT-PCR法发现3 nmo L GLP-1组大鼠胃组织NUCB2 m RNA表达量高于生理盐水组,差异有统计学意义(P0.05),而其余各组大鼠胃组织NUCB2 m RNA表达与生理盐水组比较无统计学差异(P0.05)。免疫组化结果显示3 nmo L GLP-1组胃粘膜NUCB2/nesfatin-1蛋白表达与生理盐水组、E+G组比较有统计学差异(P0.05),生理盐水组大鼠胃粘膜NUCB2/nesfatin-1蛋白表达与E+G组比较无明显差异(P0.05)。结论:PVN注射GLP-1能够促进胃组织NUCB2/nesfatin-1的表达,这一作用可能是通过激活GLP-1受体来完成的。     

中枢注射Nesfatin-1与Exendin(9-39)对大鼠摄食和胃肠动力调节的影响

目的:探讨下丘脑室旁核注射GLP-1R拮抗剂Exendin(9-39)对Nesfatin-1所致大鼠摄食和胃肠动力改变的影响及作用机制。方法:选择40只雄性Wistar大鼠,随机分成正常对照组(NC组)、Nesfatin-1组(NS组)、Exendin(9-39)组(ES组)、Nesfatin-1联合Exendin(9-39)组(NE组)。采用下丘脑室旁核(PVN)埋置套管并分别给予以上药物干预,干预前和干预后的12小时、24小时记录和比较各组大鼠的摄食、饮水及体重变化。2天后,采用甲基纤维素-酚红溶液灌胃法测各组大鼠胃排空率,实时荧光定量法(RT-PCR)检测下丘脑及胃组织GLP-1Rm RNA的表达。结果:与基础摄食量比较,NS组大鼠给药后12 h、24 h的摄食量减少(P0.05),NE组大鼠给药后12 h、24 h的摄食量减少(P0.05),但较NS组增加(P0.05);与基础饮水量比较,NS组、NE组给药后12 h饮水量减少(P0.05);与基础体重比较,NS组大鼠给药后12 h、24 h的体重降低(P0.05),NE组大鼠给药后12 h的体重降低(P0.05),但较NS组增加(P0.05);NS组大鼠给药后胃排空率较NC、NE组大鼠显著下降(P0.05),NS组大鼠下丘脑GLP-1Rm RNA的表达量较NC组增加(P0.05)。结论:中枢给予GLP-1R拮抗剂能减弱Nesfatin-1引起的摄食抑制、胃排空延迟及体重下降效应,Nesfatin-1可能通过与GLP-1的协同作用参与摄食及胃肠动力的调节。     

糖尿病大鼠下丘脑Nesfatin-1对胃运动的影响及机制研究

目的:探讨下丘脑腹内侧核Nesfatin-1对正常大鼠及糖尿病大鼠胃运动的影响及其潜在机制。方法:正常大鼠随机分为0.08μg,0.8μg,8.0μg/0.5μL Nesfatin-1组;30μg/0.5μL astressin-B组;(0.8μg Nesfatin-1+30μg astressin-B)/0.5μL组;0.5μL生理盐水(NS)组;正常羊血清+假刺激(NR+SS)组;正常羊血清+电刺激(NR+ES)组;抗NUCB2/Nesfatin-1抗体+假刺激(anti-Nn-Ab+SS)组;抗NUCB2/Nesfatin-1抗体+电刺激(anti-Nn-Ab+ES)组。制作糖尿病大鼠模型,将糖尿病大鼠随机分为0.08μg/0.5μL Nesfatin-1组;0.8μg/0.5μLNesfatin-1组;8.0μg/0.5μL Nesfatin-1组;0.5μLNS组;NR+SS组;NR+ES组;anti-Nn-Ab+SS组;anti-Nn-Ab+ES组。大鼠胃部置入感应器后腹内侧核置管,记录清醒大鼠胃运动及电刺激海马CA1区后的胃运动。结果:与生理盐水组相比,下丘脑腹内侧核注射不同浓度Nesfatin-1,大鼠胃收缩幅度和频率显著降低,下丘脑腹内侧核注射0.5μL(0.8μg Nesfatin-1+30μg astressin-B)混合液后,相比单独给予0.8μg Nesfatin-1组,大鼠胃收缩幅度和频率显著升高。大鼠下丘脑腹内侧核注射0.5μL Nesfatin-1(0.8μg),大鼠胃收缩幅度和频率显著降低,下丘脑腹内侧核注射0.5μL(0.8μg Nesfatin-1+30μg astressin-B)混合液后,相比单独给予0.8μg Nesfatin-1组,大鼠胃收缩幅度和频率显著升高。下丘脑腹内侧核注射抗NUCB2/Nesfatin-1抗体后再电刺激海马CA1区,与正常羊血清+电刺激组相比,大鼠胃收缩幅度和频率进一步增强,下丘脑腹内侧核注射抗NUCB2/Nesfatin-1抗体后再电刺激海马CA1区,与单独注射抗NUCB2/Nesfatin-1抗体+假电刺激组相比,大鼠的胃收缩幅度和频率显著增高。下丘脑腹内侧核注射抗NUCB2/Nesfatin-1抗体后再给予电刺激海马CA1区,与正常羊血清+电刺激组相比,正常大鼠和糖尿病大鼠胃运动指数均显著增加,下丘脑腹内侧核注射抗NUCB2/Nesfatin-1抗体后再电刺激海马CA1区,与单独注射抗NUCB2/Nesfatin-1抗体+假电刺激组相比,正常和糖尿病大鼠的胃运动指数均显著增高。与正常大鼠相比,电刺激海马CA1区、下丘脑腹内侧核注射抗NUCB2/Nesfatin-1抗体后再给予电刺激海马CA1区,或下丘脑腹内侧核微量注射抗NUCB2/Nesfatin-1抗体,糖尿病大鼠胃运动指数均无显著差异。结论:海马-下丘脑Nesfatin-1信号通路参与胃传入信息和胃运动调控,该作用可能与CRF系统活动有关。     

α-硫辛酸对糖尿病大鼠的肾脏保护

目的:探讨a-硫辛酸对2型糖尿病肾病的保护作用。方法:腹腔注射链脲佐菌素诱导糖尿病模型,并将大鼠分成非糖尿病组(NC),糖尿病组(DM),硫辛酸治疗组(DM+ALA),每组7只。12周后检测血糖、血脂、24小时尿蛋白定量水平,同时取大鼠肾脏,测定组织匀浆中氧化应激指标。结果:12周后,DM+ALA组较DM组的血糖、血脂水平差异无统计学意义(P>0.05),24小时尿蛋白定量差异有统计学意义(P<0.05);DM组比NC组的MDA增加,GSH、SOD减少;DM+ALA比DM组MDA减少,GSH、SOD增加,差异均有统计学意义(P<0.05);24小时尿蛋白定量与GSH、SOD水平负相关,与MDA水平正相关,差异均有统计学意义(P<0.05)。结论:a-硫辛酸能改善2型糖尿病大鼠体内的氧化应激状态,延缓糖尿病肾病进展。     

下丘脑室旁核orexin-A对大鼠摄食和胃动力影响及调控机制

目的:探讨下丘脑室旁核orexin-A对大鼠摄食和胃动力影响及调控机制。方法:采用免疫组化观察下丘脑室旁核(paraventricular nucleus,PVN)orexin受体表达情况;PVN注射orexin-A观察大鼠摄食、胃运动、胃酸分泌和胃排空的改变。结果:免疫组化实验显示大鼠PVN中存在orexin受体免疫阳性细胞。PVN注射orexin-A后,大鼠前三小时摄食增加,6 h和24 h摄食无显著改变。PVN微量注射orexin-A后,大鼠胃运动幅度和频率增加、胃排空增快并且胃酸分泌增多。[D-Lys-3]-GHRP-6可部分阻断orexin-A对摄食、胃运动、胃排空和胃酸分泌的促进作用,SB334867可完全阻断orexin-A对胃运动、胃排空和胃酸分泌的促进作用。结论:下丘脑室旁核orexin-A可能通过生长激素促泌素GHSR受体信号通路调控大鼠摄食及胃功能。     

下丘脑室旁核apelin对手术创伤大鼠心功能的保护作用（英文）

Apelin是一种新型的内源性活性肽。本研究旨在探寻下丘脑室旁核(paraventricular nucleus,PVN)apelin是否能够改善开胸手术创伤大鼠的心功能,以及是否参与了电针的保护作用。将大鼠随机分为正常对照组、开胸手术创伤组和开胸手术创伤+电针内关组,采用荧光定量PCR法检测各组大鼠PVN区apelin及其受体(apelin receptor,APJR)mRNA的表达,然后通过多通道同步记录技术观察PVN微量注射外源性apelin-13(6 mmol/L,0.1μL)对开胸手术创伤组大鼠的血压、心率以及延髓头端腹外侧区(rostral ventrolateral medulla,RVLM)神经元放电活动的影响。结果显示:与正常对照组比较,创伤组大鼠PVN区APJR m RNA的表达显著减少(P0.05),apelin mRNA的表达也有下降趋势;对开胸手术创伤大鼠施电针双侧内关穴后,PVN区APJR和apelin mRNA的表达水平又有所恢复。PVN微量注射外源性apelin-13可明显升高开胸手术创伤组大鼠的平均动脉压和心率(P0.05),RVLM神经元单位放电频率也有升高趋势。以上结果提示,PVN区apelin能够改善开胸手术创伤大鼠心功能,也可能参与了电针的保护作用。     

枸杞多糖对糖尿病大鼠视网膜神经元的保护作用及其机制

目的:观察枸杞多糖(LBP)对糖尿病大鼠视网膜神经细胞的保护作用,并探讨其作用机制。方法:18只SD大鼠随机分为3组(n=6):正常对照组(NC),糖尿病模型组(DM)和LBP治疗组(DM+LBP),通过一次性腹腔注射链脲佐菌素(STZ)的方法制备糖尿病大鼠模型。DM+LBP组按1 mg/(kg·d)剂量的LBP灌胃12周。治疗结束后检测大鼠体重、空腹血糖、视网膜活性氧簇(ROS)的生成、视网膜神经节细胞(RGCs)和无长突细胞的表达、视网膜NF-E2相关因子2(Nrf2)和血红素加氧酶-1(HO-1)的蛋白表达。结果:STZ诱导糖尿病大鼠模型造模成功率100%。与NC组相比,DM组大鼠体重明显降低、空腹血糖值升高、ROS的生成明显增加、RGCs和无长突细胞的数量均明显减少(P<0.01)。与DM组相比,LBP治疗组大鼠体重升高、血糖降低、ROS的生成减少、RGCs和无长突细胞的数量均明显增加(P<0.01或P<0.05);视网膜Nrf2和HO-1的蛋白表达均明显升高(P<0.01)。结论:LBP能改善糖尿病大鼠视网膜的氧化应激状态,对糖尿病大鼠视网膜神经细胞有一定的保护效应,其作用机制可能与其激活Nrf2/HO-1信号通路有关。     

大鼠室旁核注射orexin-A对体重的影响

目的:探讨大鼠室旁核(PVN)注射orexin-A对体重的影响。方法:大鼠室旁核(PVN)微量注射orexin-A,用大脑置管埋管、组织化学染色等方法探讨PVN注射orexin-A对其体重的影响。结果:与安慰剂组大鼠相比,PVN注射orexin-A组大鼠体重明显减轻(P0.05),而orexin-A组和安慰剂组摄食量无明显差异(P0.05)。注射结束后6天,orexin-A处理大鼠的体重仍显著低于注射前(P0.05),而安慰剂组大鼠则比注射前显著增重(P0.05)。药物注射可显著降低机体脂肪,但并不特异存在于注射orexin-A或安慰剂的大鼠身上。Orexin-A组和安慰剂组大鼠的肌肉量和脂肪量均显著降低(P0.05),但注射orexin-A的大鼠降低更明显。与安慰剂组相比,orexin-A处理后的摄食转化率显著降低(P0.05)。结论:大鼠室旁核(PVN)注射orexin-A可通过增加活动量产生负能量平衡,引起体重减轻。     

Obestatin对血浆ghrelin和nesfatin-1水平及胃排空的影响

目的:探讨侧脑室注射obestatin对大鼠血浆酰基化ghrelin、去酰基化ghrelin、nesfatin-1水平的影响以及对胃排空的调控。方法:侧脑室注射obestatin,采用酶免疫测定(EIA)法检测血浆酰基化ghrelin、去酰基化ghrelin、nesfatin-1水平以及胃排空率的变化。结果:侧脑室分别注射0.1、0.3或1.0 nmol obestatin,大鼠血浆酰基化ghrelin、去酰基化ghrelin以及nesfatin-1水平无显著改变(P0.05),且酰基化ghrelin与去酰基化ghrelin比率无显著改变(P0.05);侧脑室注射obestatin,大鼠摄食量无显著改变,但胃排空率明显增加(P0.05);胃排空率明显延迟(P0.05)。与侧脑室注射1.0 nmol Obestatin组相比,注射1.0 nmol Obestatin+CRF,大鼠摄食量无显著改变,胃排空率明显延迟(P0.05)。各组摄食量及进入十二指肠内食物量无明显差异(P0.05)。结论:中枢obestatin促进大鼠的胃排空,可能与h/r CRF通路有关。     

内源性Orexin-A调控大鼠胃运动的中枢及外周机制

目的:探讨内源性Orexin-A(OXA)对大鼠胃运动的中枢和外周作用机制。方法:选取成年Wistar大鼠为研究对象,通过禁食诱导大鼠合成内源性OXA。血浆OXA浓度采用放射免疫法测定。实验前大鼠注射OXA受体拮抗剂SB334867,观察内源性OXA的作用。迷走神经切断术用来观察迷走神经的介导作用。胃排空采用分光光度法测量,消化间期胃运动通过在胃窦部植入一应力传感器测量。Orexin前体(PPO)在胃和下丘脑组织的表达,采用蛋白印迹确定。结果:禁食18 h后,血浆OXA水平和PPO蛋白表达显著增加(P0.05),在禁食36 h组达到最高水平(P0.01)。内源性OXA促进胃排空(P0.05),抑制消化间期胃蠕动(P0.05)。外周注射SB334867均能阻断上述胃动力效应(P0.05),但对PPO表达没有影响。迷走神经切断术不能阻断内源性OXA的介导作用(P0.05)。结论:禁食能诱导内源性OXA的合成,内源性OXA能加速胃排空,同时它又抑制消化间期胃蠕动。     

糖尿病大鼠弓状核-海马肥胖抑素通路构成及对胃运动和胃排空的影响

目的: 探究糖尿病大鼠弓状核(ARC)-海马肥胖抑素(obestatin)神经通路构成,以及该通路对大鼠胃运动、胃排空的影响。方法: 健康雄性Wistar大鼠采用果糖溶液诱导胰岛素抵抗加腹腔注射链脲佐菌素的方法制备糖尿病模型,造模之后,随机分为5组:对照组(NS组)、0.1、1和10 pmol obestatin组、obestatin+NBI27914组,每组7只;各组通过置管分别向海马内注射0.5 μl 生理盐水(NS)、obestatin(0.1 pmol、1 pmol、10 pmol)和混合液(10 pmol obestatin + 60 pmol NBI27914),给药后立即记录大鼠胃运动,15 min后进行胃排空研究;通过荧光金(FG)逆行追踪及免疫组化方法比较正常及糖尿病大鼠ARC-海马obestatin神经通路构及ARC obestatin mRNA表达的异同。结果: 与正常大鼠相比,糖尿病大鼠ARC FG/obestatin双标神经元数目显著减少(P＜0.05),ARC obestatin mRNA表达量显著下降(P＜0.05);obestatin各组可剂量依赖性的抑制大鼠胃运动及胃排空(P＜0.05~0.01),obestatin的这些效应可被促肾上腺皮质激素受体1(CRFR1)阻断剂NBI27914部分阻断(P＜0.05);obestatin对糖尿病大鼠胃运动和胃排空的抑制效应显著减弱(P＜0.05)。结论: ARC-海马之间存在obestatin神经和功能通路,参与糖尿病大鼠胃运动及胃排空调控,且CRFR1信号通路参与该过程。该通路功能的减弱可能参与了糖尿病早期胃动力紊乱的发病。     

Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats

Glucagon-like peptide-1(7-36)-amide (GLP-1) is postulated to act as a hormonal signal from gut to brain to inhibit food intake and gastric emptying. A mixed-nutrient meal produces a 2 to 3-h increase in plasma GLP-1. We determined the effects of intravenous infusions of GLP-1 on food intake, sham feeding, and gastric emptying in rats to assess whether GLP-1 inhibits food intake, in part, by slowing gastric emptying. A 3-h intravenous infusion of GLP-1 (0.5-170 pmol.kg(-1).min(-1)) at dark onset dose-dependently inhibited food intake in rats that were normally fed with a potency (mean effective dose) and efficacy (maximal % inhibition) of 23 pmol.kg(-1).min(-1) and 82%, respectively. Similar total doses of GLP-1 administered over a 15-min period were less potent and effective. In gastric emptying experiments, GLP-1 (1.7-50 pmol.kg(-1).min(-1)) dose-dependently inhibited gastric emptying of saline and ingested chow with potencies of 18 and 6 pmol.kg(-1).min(-1) and maximal inhibitions of 74 and 83%, respectively. In sham-feeding experiments, GLP-1 (5-50 pmol.kg(-1).min(-1)) dose-dependently reduced 15% aqueous sucrose intake in a similar manner when gastric cannulas were closed (real feeding) and open (sham feeding). These results demonstrate that intravenous infusions of GLP-1 dose-dependently inhibit food intake, sham feeding, and gastric emptying with a similar potency and efficacy. Thus GLP-1 may inhibit food intake in part by reducing gastric emptying, yet can also inhibit food intake independently of its action to reduce gastric emptying. It remains to be determined whether intravenous doses of GLP-1 that reproduce postprandial increases in plasma GLP-1 are sufficient to inhibit food intake and gastric emptying.     

The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans

Glucagon-like peptide 1 (GLP-1) lowers glycemia by modulating gastric emptying and endocrine pancreatic secretion. Rapidly after its secretion, GLP-1-(7-36) amide is degraded to the metabolite GLP-1-(9-36) amide. The effects of GLP-1-(9-36) amide in humans are less well characterized. Fourteen healthy volunteers were studied with intravenous infusion of GLP-1-(7-36) amide, GLP-1-(9-36) amide, or placebo over 390 min. After 30 min, a solid test meal was served, and gastric emptying was assessed. Blood was drawn for GLP-1 (total and intact), glucose, insulin, C-peptide, and glucagon measurements. Administration of GLP-1-(7-36) amide and GLP-1-(9-36) amide significantly raised total GLP-1 plasma levels. Plasma concentrations of intact GLP-1 increased to 21 +/- 5 pmol/l during the infusion of GLP-1-(7-36) amide but remained unchanged during GLP-1-(9-36) amide infusion [5 +/- 3 pmol/l; P < 0.001 vs. GLP-1-(7-36) amide administration]. GLP-1-(7-36) amide reduced fasting and postprandial glucose concentrations (P < 0.001) and delayed gastric emptying (P < 0.001). The GLP-1 metabolite had no influence on insulin or C-peptide concentrations. Glucagon levels were lowered by GLP-1-(7-36) amide but not by GLP-1-(9-36) amide. However, the postprandial rise in glycemia was reduced significantly (by approximately 6 mg/dl) by GLP-1-(9-36) amide (P < 0.05). In contrast, gastric emptying was completely unaffected by the GLP-1 metabolite. The GLP-1 metabolite lowers postprandial glycemia independently of changes in insulin and glucagon secretion or in the rate of gastric emptying. Most likely, this is because of direct effects on glucose disposal. However, the glucose-lowering potential of GLP-1-(9-36) amide appears to be small compared with that of intact GLP-1-(7-36) amide.     

Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans

Glucagon-like peptide-1 (GLP-1) relaxes the stomach during fasting but decreases hunger and food consumption and retards gastric emptying. The interrelationships between volume, emptying, and postprandial symptoms in response to GLP-1 are unclear. We performed, in healthy human volunteers, a placebo-controlled study of the effects of intravenous GLP-1 on gastric volume using (99m)Tc-single photon emission computed tomography imaging, gastric emptying of a nutrient liquid meal (Ensure) using scintigraphy, maximum tolerated volume (MTV) of Ensure, and postprandial symptoms 30 min after MTV. The role of vagal cholinergic function in the effects of GLP-1 was assessed by human pancreatic polypeptide (HPP) response to the Ensure meal. GLP-1 increased fasting and postprandial gastric volumes and retarded gastric emptying; MTV and postprandial symptoms were not different compared with controls. Effects on postprandial gastric function were associated with reduced postprandial HPP levels. GLP-1 does not induce postprandial symptoms despite significant inhibition of gastric emptying and vagal function; this may be partly explained by the increase in postprandial gastric volume.     

Hyperglycemia-induced GLP-1R downregulation causes RPE cell apoptosis

Glucagon-like peptide-1 receptor (GLP-1R) is closely associated with the onset of diabetes and its complications. However, its roles in diabetic retinopathy are unknown. Retinal pigment epithelial (RPE) cells are a crucial component of the outer blood–retina barrier and their death is related to the progression of diabetic retinopathy. Thus, we examined the pathophysiological role of GLP-1R in RPE cell apoptosis. We found that GLP-1R expression was lower in the isolated neuroretina and RPE cells of streptozotocin-treated rats than in vehicle-treated rats. High-glucose treatment also decreased GLP-1R expression in a human RPE cell line (ARPE-19 cells). GLP-1R was silenced in ARPE-19 cells, in order to elucidate the pathophysiological roles of GLP-1R. This increased intracellular reactive oxygen species (ROS) generation and activated p53-mediated Bax promoter and endoplasmic reticulum (ER) stress signaling. We also found that GLP-1R knockdown-mediated p53 expression was regulated by ER stress. Interestingly, antioxidant treatment and peroxiredoxin 1 (Prx1) overexpression attenuated GLP-1R knockdown-induced ER stress signaling and p53 expression. Finally, to confirm that GLP-1R activation has protective effects, ARPE-19 cells were treated with exendin-4, a synthetic GLP-1R agonist. This attenuated high-glucose-induced ROS generation, ER stress signaling, and p53 expression. Collectively, these results indicated that hyperglycemia decreases GLP-1R expression in RPE cells. Such a decrease generates intracellular ROS, which increases ER stress-mediated p53 expression, and subsequently causes apoptosis by increasing Bax promoter activity. Our data suggested that regulation of GLP-1R expression is a promising approach for the treatment of diabetic retinopathy.     

Inhibition of gastric emptying by acarbose is correlated with GLP-1 response and accompanied by CCK release

We investigated the effect of acarbose, an alpha-glucosidase and pancreatic alpha-amylase inhibitor, on gastric emptying of solid meals of varying nutrient composition and plasma responses of gut hormones. Gastric emptying was determined with scintigraphy in healthy subjects, and all studies were performed with and without 100 mg of acarbose, in random order, at least 1 wk apart. Acarbose did not alter the emptying of a carbohydrate-free meal, but it delayed emptying of a mixed meal and a carbohydrate-free meal given 2 h after sucrose ingestion. In meal groups with carbohydrates, acarbose attenuated responses of plasma insulin and glucose-dependent insulinotropic polypeptide (GIP) while augmenting responses of CCK, glucagon-like peptide-1 (GLP-1), and peptide YY (PYY). With mixed meal + acarbose, area under the curve (AUC) of gastric emptying was positively correlated with integrated plasma response of GLP-1 (r = 0.68, P < 0.02). With the carbohydrate-free meal after sucrose and acarbose ingestion, AUC of gastric emptying was negatively correlated with integrated plasma response of GIP, implying that prior alteration of carbohydrate absorption modifies gastric emptying of a meal. The results demonstrate that acarbose delays gastric emptying of solid meals and augments release of CCK, GLP-1, and PYY mainly by retarding/inhibiting carbohydrate absorption. Augmented GLP-1 release by acarbose appears to play a major role in the inhibition of gastric emptying of a mixed meal, whereas CCK and PYY may have contributory roles.